CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $7.07B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.21: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.12%Below 5Y avg (1.16%)
Annual Rate
INR 0.50Paid unknown
Payout Ratio
14.6%Sustainable
Last Ex-Dividend
Jul 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
676.64BINR7.07B · vs all stocks (USD)
Trailing P/E
120.69xvs Biotechnology peers
Revenue (TTM)
173.21BINR1.81B · vs all stocks (USD)
Profit Margin
2.86%vs Biotechnology peers
Beta
0.3100xvs all stocks
52-Week Change
15.59%vs all stocks
Forward Annual Dividend Yield
0.12%vs all stocks
Market Capitalization
676.64BINR7.07B · vs all stocks (USD)
Enterprise Value
817.55BINR8.54B · vs all stocks (USD)
Trailing P/E
120.69xvs Biotechnology peers
Forward P/E
37.50xvs Biotechnology peers
PEG Ratio
0.5144xvs Biotechnology peers
Price to Sales (TTM)
4.03xvs Biotechnology peers
Price to Book (MRQ)
1.96xvs Biotechnology peers
Enterprise to Revenue
4.72xvs Biotechnology peers
Enterprise to EBITDA
22.82xvs Biotechnology peers
Gross Margin
65.80%vs Biotechnology peers
Profit Margin
2.86%vs Biotechnology peers
Operating Margin
6.91%vs Biotechnology peers
Return on Assets (TTM)
0.61%vs Biotechnology peers
Return on Equity (TTM)
1.05%vs Biotechnology peers
Revenue (TTM)
173.21BINR1.81B · vs all stocks (USD)
Revenue per Share (TTM)
117.85INRUpdated Aug 21, 2026Quarterly Revenue Growth
10.00%vs Biotechnology peers
Gross Profit (TTM)
105.98BINR1.11B · vs all stocks (USD)
EBITDA (TTM)
38.54BINR402.56M · vs all stocks (USD)
Net Income (TTM)
4.95BINR51.74M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
349.40%vs Biotechnology peers
Operating Cash Flow (TTM)
19.94BINR208.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.86BINR40.28M · vs all stocks (USD)
Forward Annual Dividend Rate
0.5000INRUpdated Aug 21, 2026Forward Annual Dividend Yield
0.12%vs all stocks
Trailing Annual Dividend Rate
0.00INRUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
5-Year Average Dividend Yield
1.16%vs all stocks
Payout Ratio
14.58%vs Biotechnology peers
Minority Interest (Equity)
25.90BINRFY2026 · Mar 31, 2026Revenue
167.80BINRFY2026 · Mar 31, 2026Cost of Goods Sold
56.95BINRFY2026 · Mar 31, 2026Gross Profit
110.85BINRFY2026 · Mar 31, 2026Operating Income
17.22BINR179.89M · vs all stocks (USD)
Pre-tax Income
4.48BINRFY2026 · Mar 31, 2026Income Tax Expense
791.00MINRFY2026 · Mar 31, 2026Net Income
3.69BINRFY2026 · Mar 31, 2026EBIT
14.13BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
36.53BINRFY2026 · Mar 31, 2026Research & Development
7.08BINRFY2026 · Mar 31, 2026Selling, General & Administrative
13.73BINRFY2026 · Mar 31, 2026Other Operating Expenses
19.18BINRFY2026 · Mar 31, 2026Non-operating Interest Income
1.15BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
9.65BINRFY2026 · Mar 31, 2026EPS (Basic)
2.82INRFY2026 · Mar 31, 2026EPS (Diluted)
2.82INRFY2026 · Mar 31, 2026Basic Shares Outstanding
1.37BSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
1.37BSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
3.69BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
168.00MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
5.27BINRFY2026 · Mar 31, 2026Free Cash Flow
-12.71BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
21.11BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
3.69BINRFY2026 · Mar 31, 2026Stock-based Compensation
1.64BINRFY2026 · Mar 31, 2026Other Non-cash Items
9.35BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
6.24BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-15.65BINRFY2026 · Mar 31, 2026Capital Expenditures
-17.98BINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-1.14BINRFY2026 · Mar 31, 2026Net Acquisitions
0.00INRFY2026 · Mar 31, 2026Purchase of Investments
-235.36BINRFY2026 · Mar 31, 2026Sale of Investments
232.17BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-21.16BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
2.66BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-27.08BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
349.00MINRFY2026 · Mar 31, 2026Common Stock Repurchase
-26.00MINRFY2026 · Mar 31, 2026Common Dividends Paid
-908.00MINRFY2026 · Mar 31, 2026Other Financing Charges
-59.65BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
1.36BINRFY2026 · Mar 31, 2026Shares Outstanding
1.63BSharesUpdated Aug 21, 2026Float Shares
801.82MSharesUpdated Aug 21, 2026% Held by Insiders
48.12%vs all stocks
% Held by Institutions
30.89%vs all stocks
Total Cash (MRQ)
38.83BINR405.63M · vs all stocks (USD)
Total Cash per Share (MRQ)
23.98INRUpdated Aug 21, 2026Total Debt (MRQ)
154.34BINR1.61B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4214xvs Biotechnology peers
Current Ratio (MRQ)
1.22xvs Biotechnology peers
Book Value per Share (MRQ)
210.14INRUpdated Aug 21, 2026Total Assets
636.51BINR6.65B · vs all stocks (USD)
Total Current Assets
171.80BINRFY2026 · Mar 31, 2026Total Liabilities
270.29BINRFY2026 · Mar 31, 2026Total Non-current Assets
464.71BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
129.60BINRFY2026 · Mar 31, 2026Total Current Liabilities
140.69BINRFY2026 · Mar 31, 2026Cash
11.05BINRFY2026 · Mar 31, 2026Cash Equivalents
13.11BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
24.16BINRFY2026 · Mar 31, 2026Other Short-term Investments
16.27BINRFY2026 · Mar 31, 2026Accounts Receivable
59.87BINRFY2026 · Mar 31, 2026Inventory
60.86BINRFY2026 · Mar 31, 2026Accounts Payable
67.72BINRFY2026 · Mar 31, 2026Short-term Debt
41.51BINRFY2026 · Mar 31, 2026Other Current Liabilities
388.00MINRFY2026 · Mar 31, 2026Long-term Debt
112.83BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
5.55BINRFY2026 · Mar 31, 2026Common Stock (Book)
8.11BINRFY2026 · Mar 31, 2026Retained Earnings
139.92BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
366.21BINR3.83B · vs all stocks (USD)
Treasury Stock
423.00MINRFY2026 · Mar 31, 202652-Week Low
337.05INRUpdated Aug 21, 202652-Week High
447.15INRUpdated Aug 21, 202652-Week Change
15.59%vs all stocks
Beta
0.3100xvs all stocks
50-Day MA
422.93INRUpdated Aug 21, 2026200-Day MA
394.51INRUpdated Aug 21, 2026Avg 10-Day Volume
4.04MSharesUpdated Aug 21, 2026Avg 30-Day Volume
5.79MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
3.42INRUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.66Profit Margin: 0.03
Financial Health
Altman Z-Score 2.21: grey zoneSignificant
Altman Z-Score: 2.21
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $7.07B, above the global median of $1.18BNotable
Market cap (USD): 7,068,154,762.243Global Median: 1,179,398,897.704
Revenue is $1.81B, above the global median of $534.05MNotable
Revenue (USD): 1,809,362,029.117Global Median: 534,052,387.958
Levered free cash flow is $40.28M, above the global median of $19.22MNotable
Levered free cash flow (USD): 40,279,776Global Median: 19,216,527.683
Companies that share the same coordination system — how they create, deliver, or capture value.
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
Samsung Epis Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lantheus Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Getinge AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Intuit Inc.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Innovex International Inc.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Intuitive Surgical, Inc.
1 interpretationMulti-Year Revenue, Profit, And Income Growth